TOP > クイック検索 > 外国特許検索 > THERAPEUTIC AGENT FOR INJURY IN EPITHELIUM AND ENDOTHELIUM

THERAPEUTIC AGENT FOR INJURY IN EPITHELIUM AND ENDOTHELIUM 新技術説明会

外国特許コード F130007767
掲載日 2013年12月10日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2013JP062989
国際公開番号 WO 2013162078
国際出願日 平成25年4月30日(2013.4.30)
国際公開日 平成25年10月31日(2013.10.31)
優先権データ
  • 特願2012-102910 (2012.4.27) JP
発明の名称 (英語) THERAPEUTIC AGENT FOR INJURY IN EPITHELIUM AND ENDOTHELIUM 新技術説明会
発明の概要(英語) The present invention provides: a therapeutic agent for injury in an epithelium and an endothelium, particularly minute injury in an epithelium and an endothelium; and others. The therapeutic agent according to the present invention is characterized by comprising, for example, a peptide (a) or (b) as mentioned below, a derivative of the peptide, or a salt of the peptide or the derivative: (a) a peptide comprising an amino acid sequence represented by any one of SEQ ID NOs: 10, 4, 12 and 6; and (b) a peptide comprising an amino acid sequence represented by any one of SEQ ID NOs: 16, 18, 20 and 22.
従来技術、競合技術の概要(英語) BACKGROUND ART
9 Hemostatic clotting factors that are involved in the coagulation of the long-known (F9) is an essential and blood coagulation factors, protein known as the cause of hemophilia. F9 Is, in the course of the blood coagulation reaction, coagulation factor 11 and coagulation factors 7 (F11), present between the light and heavy chains of an intermediate portion (Activation peptide (F9-AP) ) is cut off, is activated. After cutting the light and heavy chains is also connected by a disulfide bond and, as a single molecule of 1, to promote blood coagulation reaction (non-patent document 1: Textbook of Medical Physiology,10e.Arthur C. Guyton MD). However, the function of the intermediate part F9-AP hardly reported. However, epithelial cells which is one type of vascular endothelial cells, in the normal state, platelet function and coagulation line controls the fibrinolytic system, and thrombus formation within the vessel so as not functioning. In addition, the components of the blood vessel does not leak out to the outside of the inner surface of the vessel by means of a covering responsiveness. Fails by vascular endothelial cells of various acute diseases (non-patent document 2: Harrison's Principles of Internal Medicine, 18e.Dan Longo). For example, acute coronary syndrome (ACS) such as myocardial infarction, blood coagulation is the bleed site to occur only in the blood vessels occurs randomly systemic disseminated intravascular coagulation syndrome (DIC), systemic inflammatory response syndrome caused by bacteria of sepsis, the most violent and allergic disease of severe symptoms of anaphylaxis and the like. Endothelial cell damage in these diseases is very small, coagulation abnormality within the blood vessel or blood component of any leakage to the outside of the vessel and for the occurrence of severe and acute, rapid administration of the therapeutic agent and an appropriate action is required. Treatment of the acute phase of the disease, conventional, anti-hypertensive agents and anti-histamine, steroid, such as administration of anti-coagulant such as bypass surgery or invasive procedure being performed. Are different from each of the above but the pathogenesis of the disease, or vascular endothelial cell dysfunction, interstitial of plasma components caused thereby is leaking to, influences the prognosis of these diseases is turning. Therefore, more rapid repair of the epithelial and endothelial injury and improving the function of the therapeutic agents that can be required in the clinical field. However, the therapeutic agents of the conventional epithelial and endothelial damage, any therapeutic effect is obtained quickly and did not.
In such a situation, the treatment of epithelial and endothelial damage, especially epithelial and endothelial micro rapid and effective treatment of injuries to carry out the development of therapeutic agents has been desired. The present invention is, in consideration of the above circumstances with an object, shown below, epithelial and endothelial injury therapeutic agent, to enhance epithelial and endothelial cells of extension of the agent, the therapeutic agent or a pharmaceutical composition comprising a hyper-extension agent (for example, epithelial and endothelial damage and diseases associated with pharmaceutical composition for the treatment of disease states or conditions) system according to the invention and the like. (1) - (F) the following (a) the peptide either, its derivatives or a salt thereof. (a) Of SEQ ID NO:10, 4, 12 and 6 comprising an amino acid sequence shown in any of. (b) And 22 of the sequence shown in any of 16, 18, 20 comprising an amino acid sequence. (c) And 6 of SEQ ID NO:10, 4, 12 in amino acid sequence shown in any of 1 or an amino acid deletion, substitution or addition of the amino acid sequence, and, or epithelial and endothelial damage repair activity enhancing epithelial and endothelial cells of extension of the peptide having the activity. (d) And 22 of SEQ ID NO:16, 18, 20 in amino acid sequence shown in any of 1 or an amino acid deletion, substitution or addition of the amino acid sequence, and, epithelial and endothelial damage repair activity enhancing epithelial and endothelial cells of stretch or a peptide having the activity. (e) And SEQ ID NO:10, 4, 12 to the amino acid sequence shown in any of the 6, 80% amino acid sequence having a homology of at least, and, epithelial and endothelial damage repair activity or enhance epithelial and endothelial cells of extension of the peptide having the activity. (f) And 22 of the sequence shown in any of 16, 18, 20 to the amino acid sequence, 80% amino acid sequence having a homology of at least, and, epithelial and endothelial damage repair activity or enhance epithelial and endothelial cells of extension of the peptide having the activity. The (1) peptide, its derivatives or a salt thereof in, epithelial and endothelial damage may include, for example micro-damage and the like. (2) - (F) the following (a) the peptide either, its derivatives or salts thereof and, the therapeutic agent of the epithelial and endothelial injury. (a) Of SEQ ID NO:10, 4, 12 and 6 comprising an amino acid sequence shown in any of. (b) And 22 of the sequence shown in any of 16, 18, 20 comprising an amino acid sequence. (c) And 6 of SEQ ID NO:10, 4, 12 in amino acid sequence shown in any of 1 or an amino acid deletion, substitution or addition of the amino acid sequence, and, a peptide having the activity of the epithelial and endothelial injury repair. (d) And 22 of SEQ ID NO:16, 18, 20 in amino acid sequence shown in any of 1 or an amino acid deletion, substitution or addition of the amino acid sequence, and, a peptide having the activity of the epithelial and endothelial injury repair. (e) And SEQ ID NO:10, 4, 12 to the amino acid sequence shown in any of the 6, 80% amino acid sequence having a homology of at least, and, a peptide having the activity of the epithelial and endothelial injury repair. (f) And 22 of the sequence shown in any of 16, 18, 20 to the amino acid sequence, 80% amino acid sequence having a homology of at least, and, a peptide having the activity of the epithelial and endothelial injury repair. In the above-described (2) therapeutic agent, epithelial and endothelial damage may include, for example, and micro-damage. (3) - (F) the following (a) the peptide either, its derivatives or salts thereof characterized in that, the extension of the epithelial and endothelial cells enhance agent. (a) Of SEQ ID NO:10, 4, 12 and 6 comprising an amino acid sequence shown in any of. (b) And 22 of the sequence shown in any of 16, 18, 20 comprising an amino acid sequence. (c) And 6 of SEQ ID NO:10, 4, 12 in amino acid sequence shown in any of 1 or an amino acid deletion, substitution or addition of the amino acid sequence, and, epithelial and endothelial cells to enhance the extension of a peptide having the activity. (d) And 16, 18, 20 SEQ ID NO:22 in the amino acid sequence shown in any of the 1 or an amino acid deletion, substitution or addition of the amino acid sequence, and, epithelial and endothelial cells to enhance the extension of a peptide having the activity. (e) And SEQ ID NO:10, 4, 12 to the amino acid sequence shown in any of the 6, 80% amino acid sequence having a homology of at least, and, epithelial and endothelial cells to enhance the extension of a peptide having the activity. (f) And 22 of the sequence shown in any of 16, 18, 20 to the amino acid sequence, 80% amino acid sequence having a homology of at least, and, epithelial and endothelial cells to enhance the extension of a peptide having the activity. (4) Animals enhancing agent as defined above (3) comprising administering to the extension, the extension of the epithelial and endothelial cells to enhance the method. (5) Extension of the enhancing agent mentioned (2) above (3) or, the pharmaceutical composition. The pharmaceutical compositions described above (5) is, for example, diseases associated with epithelial and endothelial injury and the like used in the treatment of disease states or conditions. Here, the epithelial and endothelial damage may include, for example, and micro-damage, as the disease or condition, for example, sepsis, arteriosclerosis, acute myocardial infarction, angina pectoris, arteriovenous thrombosis, bronchial asthma as well as cerebral edema after cerebral infarction and vascular hyperpermeability state at least one selected from the group consisting of 1 species. (6) Animals as defined above (5) comprising administering a pharmaceutical composition, the disease or condition associated with epithelial and endothelial injury treatment. In the above method (6), epithelial and endothelial damage may include, for example, and micro-damage, as the disease or condition, for example, sepsis, arteriosclerosis, acute myocardial infarction, angina pectoris, arteriovenous thrombosis, bronchial asthma as well as cerebral edema after cerebral infarction and vascular hyperpermeability state at least one selected from the group consisting of 1 species. According to the present invention, the therapeutic agent of the epithelial and endothelial damage, especially epithelial and endothelial micro damage therapeutic agent can be provided. In addition, the extension of the epithelial and endothelial cells enhance agent can also be provided. The therapeutic agent or enhancing agent is extended, epithelial and endothelial injury (particularly minute damage) associated with the disease or condition used in the treatment of various types can be achieved, to be very useful. In addition, the therapeutic agent and extension enhancing agent is, in view the effects, and cell gap between the intercellular adhesion enhancing agents can be used as the shrinkage agent. This is, for example, 4 and 8 will be described later as the result of the embodiment of the present can be understood.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIHON UNIVERSITY
  • 発明者(英語)
  • HIDAI, Chiaki
  • KITANO, Hisataka
  • MAMIYA, Atsushi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
日本大学産官学連携知財センター(通称NUBIC,ニュービック)は,技術移転機関と知的財産本部の機能を兼ね備えた日本大学の産学連携の窓口です。
NUBICは,日本大学全教職員や大学院生・学部学生の豊富なアイデアや研究成果を,知的財産として戦略的に創出・保護・管理し,産業界のニーズとのマッチングを図り,企業の研究開発,新製品開発,新規事業の立上げが円滑に行われるようサポートいたします。
お気軽にご相談ください。

PAGE TOP

close
close
close
close
close
close